Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.

Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF.

Leuk Res. 2013 Mar;37(3):300-4. doi: 10.1016/j.leukres.2012.11.001. Epub 2012 Dec 27.

PMID:
23273539
2.

Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.

Tyler T.

Ann Pharmacother. 2009 May;43(5):920-7. doi: 10.1345/aph.1L570. Epub 2009 Mar 31. Review.

PMID:
19336654
4.
5.

New dosing schedules of dasatinib for CML and adverse event management.

Wong SF.

J Hematol Oncol. 2009 Feb 23;2:10. doi: 10.1186/1756-8722-2-10. Review.

6.
7.

Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.

Shayani S.

Ther Drug Monit. 2010 Dec;32(6):680-7. doi: 10.1097/FTD.0b013e3181f4d9c5. Review.

PMID:
20864900
8.

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.

Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J.

Blood. 2006 Oct 15;108(8):2811-3. Epub 2006 Jun 29. Review.

9.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R.

Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420. Review.

Supplemental Content

Support Center